ArticleAJNR. American journal of neuroradiology2009
Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features.
Article in AJNR. American journal of neuroradiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 3 syntheses or guidelines pooled it, 322 citations in OpenAlex.
- Consecutive PRES and diffuse alveolar hemorrhage in a patient with active lupus nephritis and antiphospholipid antibodies: a case report and systematic literature review.BMC nephrology · 2026Pooled it
- Frequency of ischaemic stroke and intracranial haemorrhage in patients with reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) - A systematic review.European journal of neurology · 2024Pooled it
- Brain MRI findings in COVID-19 patients with PRES: A systematic review.Clinical imaging · 2022Pooled it
- Hemorrhagic posterior reversible encephalopathy syndrome with pontine infarction in early-onset eclampsia: An atypical MRI spectrum.Radiology case reports · 2026Article
- Atypical Posterior Reversible Encephalopathy Syndrome with Intraventricular Hemorrhage in a Patient with Eclampsia : A Case Report.Journal of Korean Neurosurgical Society · 2026Article
- Article
- Intracranial hemorrhage in posterior reversible encephalopathy syndrome: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- Late Postpartum Eclampsia with Posterior Reversible Encephalopathy Syndrome and Subarachnoid Hemorrhage: A Case Study.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Magnetic resonance imaging patterns and perfusion changes of posterior reversible encephalopathy syndrome in children with clinical outcome correlation.Pediatric radiology · 2024Observational
- Clinical features and outcomes of posterior reversible encephalopathy syndrome after heart transplantation: a case series.Clinical transplantation and research · 2024Article
- Fatal PRES and super-refractory status epilepticus after combined heart and kidney transplant: A case report and literature review.JHLT open · 2024Review
- Article
- Pediatric Posterior Reversible Encephalopathy Syndrome: A Review With Emphasis on Neuroimaging Characteristics.Cureus · 2023Review
- Article
- Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.Annals of hematology · 2023Article
- Posterior reversible encephalopathy syndrome following uneventful clipping of an unruptured intracranial aneurysm: A case report.World journal of clinical cases · 2023Article
- Article
- Article
- Coronavirus Disease: Subacute to Chronic Neuroimaging Findings.Neuroimaging clinics of North America · 2023Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHemorrhage is known to occur in posterior reversible encephalopathy syndrome (PRES), but the characteristics have not been analyzed in detail. The purpose of this study was to evaluate the imaging and clinical features of hemorrhage in PRES. MATERIALS AND
methodsRetrospective assessment of 151 patients with PRES was performed, and 23 patients were identified who had intracranial hemorrhage at toxicity. Hemorrhage types were identified and tabulated, including minute focal hemorrhages (<5 mm), sulcal subarachnoid hemorrhage, and focal hematoma. Clinical features of hemorrhage and nonhemorrhage PRES groups were evaluated, including toxicity blood pressure, coagulation profile/platelet counts, coagulation-altering medication, and clinical conditions associated with PRES. Toxicity mean arterial pressure (MAP) groups were defined as normal (<106 mm Hg), mildly hypertensive (106-116 mm Hg), or severely hypertensive (>116 mm Hg).
resultsThe overall incidence of hemorrhage was 15.2%, with borderline statistical significance noted between the observed clinical associations (P = .07). Hemorrhage was significantly more common (P = .02) after allogeneic bone marrow transplantation (allo-BMT) than after solid-organ transplantation. The 3 hemorrhage types were noted with equal frequency. A single hemorrhage type was found in 16 patients, with multiple types noted in 7. Patients undergoing therapeutic anticoagulation were statistically more likely to develop hemorrhage (P = .04). No difference in hemorrhage incidence was found among the 3 blood pressure subgroups (range, 14.9%-15.9%).
conclusionsThree distinct types of hemorrhage (minute hemorrhage, sulcal subarachnoid hemorrhage, hematoma) were identified in PRES with equal frequency. The greatest hemorrhage frequency was seen after allo-BMT and in patients undergoing therapeutic anticoagulation. Hemorrhage rate was independent of the toxicity blood pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.